PUBLIC COMPANY
saveZydus Lifesciences Ltd
updated 2mo ago
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Primarily engaged in the manufacturing of generic drugs, the company ranked 100th in the Fortune India 500 list in 2020.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval64 co-mentions · 32 sources
- tagRecall32 co-mentions · 32 sources
- tagSmall Molecule29 co-mentions · 29 sources
- drugCHLORPROMAZINE HYDROCHLORIDE11 co-mentions · 11 sources
- companyNorthstar Rx LLC8 co-mentions · 8 sources
- drugVigafyde7 co-mentions · 7 sources
- drugSABRIL7 co-mentions · 7 sources
- drugVIGABATRIN7 co-mentions · 7 sources
pipeline
1
marketed
0
phase 3
0
catalysts ytd
13
approvals ytd
13
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase4A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)
- phase2A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
- phase2Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis
- phase1A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
- phase3A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)
- phase4A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
🐶 Hiring Signal
News
- Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease assetMereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.biospace · 1mo ago
- Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drugSentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.fiercebiotech · 1mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that